Trial intelligence / Profile preview

DP001 in Secondary Hyperparathyroidism

NCT01653379Phase 2Completed

Sponsor
Deltanoid Pharmaceuticals
Start
Aug 2012
Primary completion
Jul 2014
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of DP-001 in secondary hyperparathyroidism (SHPT), sponsored by Deltanoid Pharmaceuticals. Started Aug 2012; status: completed.

02

Drugs

DP-001
03

Conditions

secondary hyperparathyroidism (SHPT)

Beyond the preview

Go deeper on NCT01653379.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01653379.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call